MedTrace Logo

Prophylactic Nepafenac and Ketorolac Versus Placebo in Patients Undergoing Cataract Surgery

NCT01395069 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2016-01-13

No results posted yet for this study

Summary

Assess prophylactic efficacy of topical non-steroidal anti-inflammatory drops in preventing macular edema. Patient undergoing uncomplicated cataract surgery will be enrolled and randomized to nepafenac, ketorolac, or placebo. Follow-up will occur at 1 month with ocular coherence tomography (OCT).

Conditions

  • Macular Edema

Interventions

DRUG

Nepafenac 0.1%

1 drop QID for 1 month

DRUG

Ketorolac 0.5%

1 drop QID for 1 month

OTHER

Placebo (sterile saline drops)

1 drop QID for 1 month

Sponsors & Collaborators

  • Queen's University

    lead OTHER

Principal Investigators

  • Sherif El-Defrawy, MD PhD · Queen's University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01395069 on ClinicalTrials.gov